Home>Topics>Stocks>GlaxoSmithKline PLC ADR

GlaxoSmithKline PLC ADR GSK

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. BRIEF- GSK submits application for Japanese approval of asthma drug

      Headlines

      Fri, 22 May 2015

      * Submits Japan regulatory application for mepolizumab in severe eosinophilic asthma

    2. Hunt for AIDS cure accelerates as GSK and U.S. experts link up

      Headlines

      Sun, 10 May 2015

      LONDON, May 11 (Reuters) - Britain's GlaxoSmithKline , which decided last week to retain rather than float off its HIV drugs business, is to collaborate with U.S. scientists in developing a cure for AIDS.

    3. UPDATE 2-New GSK chairman backs CEO Witty to stay at helm

      Headlines

      Thu, 7 May 2015

      LONDON, May 7 (Reuters) - GlaxoSmithKline's new chairman Philip Hampton has thrown his support behind the company's current structure and chief executive despite pressure from some shareholders for a...

    4. New GSK chairman backs CEO Witty to stay at helm

      Headlines

      Thu, 7 May 2015

      LONDON, May 7 (Reuters) - GlaxoSmithKline's new chairman Philip Hampton expressed support for the company's current structure and its chief executive on Thursday while speaking to reporters after the drugmaker's annual meeting.

    5. BRIEF- GSK appoints Manvinder Singh Banga as non-executive director

      Headlines

      Thu, 7 May 2015

      * Manvinder Singh (Vindi) Banga will join board of company as a non-executive director on 1 September, 2015

    6. GSK sees little prospect of U.S. generic Advair in 2016

      Headlines

      Wed, 6 May 2015

      LONDON, May 6 (Reuters) - After relying for years on its top-selling lung drug Advair, GlaxoSmithKline is now braced for the worst in the form of cheap generics - but not just yet.

    7. UPDATE 2- GSK scraps plan to list HIV drugs business and shields dividend

      Headlines

      Wed, 6 May 2015

      * Q1 revenue 5.62 billion pounds, in line with consensus (Adds reaction and context)

    8. Keeping Fair Value as GSK Posts In-Line 1Q and Issues Optimistic Guidance; Dividend Outlook is Shaky

      Commentary

      Wed, 6 May 2015

      Following Glaxo’s in-line first quarter and better-than-expected long-term guidance, we are holding firm to our fair value estimate of $47/GBX 1,510 (ADR/local). At current market prices, the stock looks fairly valued and carries a high but shaky dividend yield. We continue to support the company’s

    9. Gene therapy takes step forward as GSK files for EU approval

      Headlines

      Tue, 5 May 2015

      LONDON, May 5 (Reuters) - GlaxoSmithKline said on Tuesday it had submitted a gene therapy for approval in Europe, becoming the first big drugmaker to seek marketing authorisation for the technology to fix faulty genes.

    10. BRIEF- GSK submits gene therapy marketing application to EMA

      Headlines

      Tue, 5 May 2015

      * Announce EU regulatory submission for gene therapy to treat rare disease ADA-SCID

    « Prev12345Next »
    Content Partners